Venous thromboembolism risk in sarcoma patients receiving combined immune checkpoint inhibitors and VEGF pathway inhibitors: a real-world cohort study Authors: Rahul Kumar, Rohan A Phadke, Andrew Bouras, Harlene Kaur, Samer G Salman, Sai Sarnala, Swapna Vaja, Dylan Riley, Samuel W Rice, Marta Batus, Alan Blank Published: 2026 ABSTRACT AbstractBackgroundImmune checkpoint inhibitors (ICIs) and vascular endothelial growth factor (VEGF) pathway inhibitors are increasingly used in bone and soft tissue sarcomas. Risks associated with combination therapy, such as venous thromboembolism (VTE), carry significant consequences but remain poorly characterized. This study evaluated whether adding a VEGF pathway inhibitor to ICI therapy increases VTE risk in sarcoma patients.MethodsUsing the TriNetX U.S. Collaborative Network, we identified patients with bone or soft tissue sarcoma [International Classification of Diseases (ICD)-10 C40, C41, C47, C49] who received either combination therapy (ICI plus VEGF pathway inhibitor within ±30 days of ICI initiation) or ICI monotherapy. Propensity score matching (1:1) balanced cohorts for age, sex, race, hypertension, diabetes, obesity, and smoking history. The primary outcome was 1-year VTE incidence (pulmonary embolism or venous thrombosis). Hazard ratios (HRs) with 95% confidence intervals (CIs) were calculated using Cox proportional hazards models.ResultsAfter matching, 834 patients remained in each cohort (mean age 63 years; hypertension prevalence 60%). At 1 year, VTE occurred in 14.0% of the combination cohort and 12.4% of the monotherapy cohort (HR 1.23; 95% CI: 0.91–1.66; P=0.07), corresponding to an absolute risk difference of 1.6 percentage points (95% CI: −2.1 to 5.2). Musculoskeletal toxicity did not differ between groups (5.5% vs. 6.4%; HR 0.93; 95% CI: 0.61–1.41; P=0.82).ConclusionsSarcoma patients receiving ICI-based therapy experienced a high 1-year VTE burden. Although we did not detect a statistically significant increase in VTE with the addition of a VEGF pathway inhibitor, the point estimates were compatible with a modestly higher risk; however, the CIs were wide and included no difference between groups. These findings support clinical vigilance and risk assessment and motivate prospective studies of risk-adapted thromboprophylaxis in this population.Keywords: Sarcoma, venous thromboembolism (VTE), immune checkpoint inhibitors (ICIs), vascular endothelial growth factor pathway inhibitors (VEGF pathway inhibitors) Highlight box Key findings • In a propensity-matched real-world cohort of sarcoma patients, the 1-year venous thromboembolism (VTE) rate was 14.0% with combination immune checkpoint inhibitor (ICI) and vascular endothelial growth factor (VEGF) pathway inhibitor therapy versus 12.4% with ICI monotherapy [hazard ratio (HR) 1.23; 95% confidence interval (CI): 0.91–1.66; P=0.07]. Musculoskeletal toxicity was similar across groups (5.5% vs. 6.4%; HR 0.93; 95% CI: 0.61–1.41). What is known and what is new? • Both ICIs and VEGF pathway inhibitors independently promote VTE through distinct procoagulant mechanisms, yet their combined thrombotic risk in sarcoma remains poorly characterized. • This study provides real-world evidence that sarcoma patients receiving ICI-based therapy face a high absolute VTE burden, with a numerically but not statistically significant increase observed when a VEGF pathway inhibitor is added. What is the implication, and what should change now? • The high absolute VTE rates in both cohorts underscore the need for systematic thrombotic risk assessment in sarcoma patients receiving ICI-based therapy. Prospective studies incorporating sarcoma-specific risk factors, histologic subtype, and disease stage are needed to develop evidence-based thromboprophylaxis strategies for this population. Introduction Venous thromboembolism (VTE) represents a critical complication in cancer care, occurring at rates 4- to 7-fold higher than in the general population and contributing substantially to cancer-related morbidity and mortality (1). Among cancer patients, those with bone and soft tissue sarcomas face particularly severe consequences from thrombotic events: VTE delays definitive surgery, complicates limb-salvage procedures, impairs wound healing, and disrupts postoperative rehabilitation essential for functional recovery (1-3). Despite this clinical significance, the thrombotic risk profile of contemporary systemic therapies in sarcoma remains inadequately characterized. Immune checkpoint inhibitors (ICIs) and vascular endothelial growth factor (VEGF) pathway inhibitors have emerged as important treatment options for advanced sarcoma (4,5). ICIs, including anti-programmed death-1 (PD-1) and anti-programmed death ligand-1 (PD-L1) agents, demonstrate response rates of 15–40% in selected sarcoma subtypes, particularly undifferentiated pleomorphic sarcoma, alveolar soft part sarcoma, and dedifferentiated liposarcoma (6-8). VEGF pathway inhibitors, including both monoclonal antibodies (bevacizumab) and tyrosine kinase inhibitors (pazopanib, sunitinib, axitinib, sorafenib), have established efficacy in multiple sarcoma histologies and constitute standard treatment options for patients with advanced disease (9-11). However, both drug classes carry established vascular toxicity. Recent population-based studies demonstrate that ICI therapy is associated with VTE rates of 7.4–13% at 6–12 months, with the risk appearing 4- to 23-fold higher than in matched cancer patients not receiving ICIs (12-14). The prothrombotic mechanisms involve immune activation, the release of inflammatory cytokines, neutrophil extracellular trap formation, and endothelial dysfunction (15,16). Combination ICI regimens, particularly dual PD-1/CTLA-4 blockade, confer substantially higher VTE risk than monotherapy, with some series reporting 1-year cumulative incidences exceeding 29% (17,18). VEGF pathway inhibitors similarly promote thrombosis through multiple mechanisms: disruption of endothelial nitric oxide production, impaired endothelial regeneration, exposure of subendothelial procoagulant surfaces, and increased blood viscosity secondary to erythropoietin overproduction (19-21). Population-based studies demonstrate VTE incidence rates of 2.5–8.8% at 3 years with various VEGF-targeted agents, with both monoclonal antibodies and tyrosine kinase inhibitors conferring significant thrombotic risk (22-24). Combination regimens employing ICIs with VEGF pathway inhibitors are increasingly used in sarcoma based on mechanistic synergy and promising efficacy signals (25-27). VEGF inhibition modifies the immunosuppressive tumor microenvironment, potentially enhancing ICI efficacy, while ICIs may overcome resistance mechanisms to antiangiogenic therapy (28,29). However, such combinations also intensify adverse events, with grade ≥3 toxicity rates approaching 60% in some trials (30,31). The specific thrombotic risk of combination ICI and VEGF pathway inhibitor therapy remains poorly defined in sarcoma. Given the rarity of these tumors and the relatively recent introduction of these agents into sarcoma treatment paradigms, prospective trials adequately powered to detect differences in VTE rates are not feasible. This study aimed to evaluate whether adding a VEGF pathway inhibitor to ICI therapy increases the 1-year risk of VTE in patients with bone and soft tissue sarcoma, utilizing a large real-world electronic health record database to overcome the sample size limitations inherent to this rare tumor population. We present this article in accordance with the STROBE reporting checklist (available at https://tcr.amegroups.com/article/view/10.21037/tcr-2026-0564/rc). Methods Data source Data were derived from the TriNetX U.S. Collaborative Network, a federated research platform containing de-identified electronic medical records from approximately 120 million patients across participating healthcare organizations. TriNetX integrates structured data elements, including diagnoses, procedures, laboratory results, and medication prescriptions, allowing large-scale real-world analyses. This study was conducted in accordance with the Declaration of Helsinki and its subsequent amendments. All data were de-identified in accordance with Health Insurance Portability and Accountability Act (HIPAA) requirements, and the study was deemed exempt from institutional review board approval. Study population Eligible patients were adults (≥18 years) with a diagnosis of malignant neoplasm of bone, articular cartilage, or soft tissue [International Classification of Diseases (ICD)-10 C40, C41, C47, C49]. Patients were required to have documented exposure to an ICI, either as monotherapy or in combination with a VEGF pathway inhibitor. Cohort definitions Two medication-exposure cohorts were defined: ❖ Combination therapy cohort: patients receiving an ICI (pembrolizumab, nivolumab, ipilimumab, atezolizumab) concurrently with a VEGF pathway inhibitor (pazopanib, sunitinib, sorafenib, axitinib, bevacizumab). Concurrent exposure was approximated by requiring a VEGF pathway inhibitor prescription within ±30 days of ICI initiation. This narrow co-prescription window was selected to capture treatment intent for concurrent therapy at the point of prescribing; broader windows would introduce greater uncertainty regarding true temporal overlap of drug exposure. Prescription overlap does not confirm true co-exposure or adherence, and the duration of therapy was not uniformly available. ❖ Combination therapy cohort: patients receiving an ICI (pembrolizumab, nivolumab, ipilimumab, atezolizumab) concurrently with a VEGF pathway inhibitor (pazopanib, sunitinib, sorafenib, axitinib, bevacizumab). Concurrent exposure was approximated by requiring a VEGF pathway inhibitor prescription within ±30 days of ICI initiation. This narrow co-prescription window was selected to capture treatment intent for concurrent therapy at the point of prescribing; broader windows would introduce greater uncertainty regarding true temporal overlap of drug exposure. Prescription overlap does not confirm true co-exposure or adherence, and the duration of therapy was not uniformly available. ❖ ICI monotherapy cohort: patients receiving an ICI without any documented VEGF pathway inhibitor exposure. ❖ ICI monotherapy cohort: patients receiving an ICI without any documented VEGF pathway inhibitor exposure. Outcomes The primary outcome was VTE, defined as the first diagnosis of pulmonary embolism (I26) or venous embolism/thrombosis (I82) occurring within 1 year of index treatment initiation. The secondary outcome was musculoskeletal toxicity, defined as myositis (M60) or myalgia (M79.1), reflecting clinically relevant immune-related adverse events that may impair rehabilitation or post-surgical recovery in sarcoma patients. This secondary endpoint was exploratory and was not prespecified with a formal hypothesis or multiplicity adjustment. Index date and exposure handling The index date for both cohorts was defined as the date of the first ICI prescription. For the combination therapy cohort, patients were required to have a VEGF pathway inhibitor prescription within ±30 days of this index date to approximate concurrent exposure. Patients who received ICI monotherapy initially and later added a VEGF pathway inhibitor beyond the 30-day window remained in the monotherapy cohort for the primary analysis. Follow-up began at the index date, and patients were censored at death, loss to follow-up, or 365 days, whichever occurred first. Covariates and propensity score matching Baseline covariates included age, sex, race, and comorbidities reliably captured in TriNetX: hypertension (I10), type 2 diabetes (E11), overweight/obesity (E66), and nicotine dependence (Z87.891). Propensity score matching (1:1) was performed using logistic regression with a nearest-neighbor algorithm without replacement and a caliper of 0.2 standard deviations of the logit of the propensity score. Covariate balance was assessed using standardized mean differences, with values <0.1 considered well-balanced. Oncology-specific variables such as disease stage, sarcoma subtype, metastatic burden, Eastern Cooperative Oncology Group (ECOG) performance status, and prior lines of therapy were not consistently available and could not be included, creating a risk of residual confounding by indication for VEGF inhibitors (e.g., more advanced disease in the combination group). Statistical analysis Time-to-event outcomes were analyzed using Kaplan-Meier survival curves, and differences between cohorts were assessed with the log-rank test. Hazard ratios (HRs) with 95% confidence intervals (CIs) were calculated using Cox proportional hazards models. Two-sided P values <0.05 were considered statistically significant. Absolute risk differences were also calculated. Sensitivity analyses were performed to evaluate the impact of differential follow-up duration and potential misclassification of medication exposure. Results Patient characteristics The initial query identified 835 patients who received combination therapy and 10,413 who received ICI monotherapy. After 1:1 propensity score matching, 834 patients remained in each cohort (Figure 1). Matching achieved balance across demographics and comorbidities, with a mean age of 63 years, 60% prevalence of hypertension, and 39% with a history of nicotine dependence in both cohorts (Table 1). Race and sex distributions were also similar across cohorts. Median follow-up duration was 11.2 months [interquartile range (IQR) 9.1–12.0 months] for the combination cohort and 11.0 months (IQR 8.9–12.0 months) for the monotherapy cohort. STROBE flow diagram showing patient cohort selection. ICD-10, International Classification of Diseases, 10th Revision; ICI, immune checkpoint inhibitor; MSK, musculoskeletal; SD, standard deviation; VEGF, vascular endothelial growth factor; VTE, venous thromboembolism. Table 1Patient characteristics and demographicsVariableCombination cohortMonotherapy cohortPatients after matching, n834834Age, years, mean (SD)62.7 (16.3)62.9 (16.0)Hypertension prevalence60%60%History of nicotine dependence39%39%Sex Male56.6%56.7% Female43.4%43.3%Race White69.6%79.4% Black/African American8.1%7.2% Asian8.6%5.9%Ethnicity Hispanic/Latino7.5%4.7% Not Hispanic/Latino78.2%79.7% Unknown14.3%14.2%Median follow-up, months (IQR)11.2 (9.1–12.0)11.0 (8.9–12.0)IQR, interquartile range; SD, standard deviation. Patient characteristics and demographics IQR, interquartile range; SD, standard deviation. VTE Because patients with prior VTE were excluded from the VTE risk set, the number at risk is lower than the matched cohort size (635 vs. 684 patients). This exclusion was applied after propensity score matching using any prior recorded diagnosis of pulmonary embolism (I26) or venous thrombosis (I82) at any time before the index date, with no minimum lookback period restriction. Accordingly, the matched sample sizes differ from the VTE risk set. At 1 year, VTE occurred in 89 of 635 at-risk patients (14.0%) in the combination therapy cohort and 85 of 684 at-risk patients (12.4%) in the monotherapy cohort (Tables 2,3). Kaplan-Meier analysis showed modest divergence of VTE-free survival curves over the 12-month follow-up, though the log-rank test did not reach statistical significance (χ2=1.89, P=0.17). Cox proportional hazards analysis yielded an HR of 1.23 (95% CI: 0.91–1.66; P=0.07). We did not detect a statistically significant difference in VTE risk; however, the point estimate suggests a possible increase with combination therapy. The absolute risk difference was 1.6 percentage points (95% CI: −2.1 to 5.2), which is compatible with a range from modest benefit to modest increase in risk. Table 2Primary outcome: venous thromboembolism patient cohorts (pulmonary embolism or venous thrombosis)MeasureCombination therapyICI monotherapyPatients at risk†635684Patients with VTE89851-year VTE risk (%)14.012.4†, patients with VTE prior to the index date were excluded (199 combination, 150 monotherapy). ICI, immune checkpoint inhibitor; VTE, venous thromboembolism. Primary outcome: venous thromboembolism patient cohorts (pulmonary embolism or venous thrombosis) †, patients with VTE prior to the index date were excluded (199 combination, 150 monotherapy). ICI, immune checkpoint inhibitor; VTE, venous thromboembolism. Table 3Primary outcome: venous thromboembolism statistical analysis (pulmonary embolism or venous thrombosis)StatisticValue95% CIP valueRisk difference0.016−0.021 to 0.0520.39Risk ratio1.130.86 to 1.49–Odds ratio1.150.84 to 1.58–Hazard ratio1.230.91 to 1.660.07Log-rank χ2 (df=1)1.89–0.17CI, confidence interval. Primary outcome: venous thromboembolism statistical analysis (pulmonary embolism or venous thrombosis) CI, confidence interval. Musculoskeletal toxicity Musculoskeletal adverse events (myositis or myalgia) occurred in 40 of 727 at-risk patients (5.5%) in the combination cohort and 49 of 760 at-risk patients (6.4%) in the monotherapy cohort (Tables 4,5). Cox proportional hazards analysis yielded an HR of 0.93 (95% CI: 0.61–1.41; P=0.82). We did not detect evidence of an increased risk of musculoskeletal toxicity with the addition of a VEGF pathway inhibitor in this population. Table 4Secondary outcome: musculoskeletal toxicity patient cohorts (myositis or myalgia)MeasureCombination therapyICI monotherapyPatients at risk†727760Patients with outcome40491-year risk (%)5.56.4†, patients with outcome prior to the index date were excluded (107 combination, 74 monotherapy). ICI, immune checkpoint inhibitor. Secondary outcome: musculoskeletal toxicity patient cohorts (myositis or myalgia) †, patients with outcome prior to the index date were excluded (107 combination, 74 monotherapy). ICI, immune checkpoint inhibitor. Table 5Secondary outcome: musculoskeletal toxicity statistical analysis (myositis or myalgia)StatisticValue95% CIP valueRisk difference−0.009−0.034 to 0.0150.44Risk ratio0.850.57 to 1.28–Odds ratio0.850.55 to 1.30–Hazard ratio0.930.61 to 1.410.82Log-rank χ2 (df=1)0.12–0.73CI, confidence interval. Secondary outcome: musculoskeletal toxicity statistical analysis (myositis or myalgia) CI, confidence interval. Discussion This real-world analysis of 834 propensity-matched sarcoma patients demonstrates a substantial 1-year VTE burden in patients receiving ICI-based therapy, with 14.0% of those on combination ICI and VEGF pathway inhibitor therapy and 12.4% on ICI monotherapy experiencing VTE. The point estimate suggests a modestly higher VTE risk with combination therapy (HR 1.23), but the CI is wide (0.91–1.66) and includes no difference. Our study was likely underpowered to detect smaller, yet clinically relevant, differences. For sarcoma patients, understanding the thrombotic risk of combination therapy carries particular clinical importance. Unlike many solid tumors, where VTE primarily affects medical management and anticoagulation decisions, thrombotic events in sarcoma directly impact surgical candidacy, the feasibility of limb-sparing approaches, perioperative bleeding risk when therapeutic anticoagulation is required, and rehabilitation capacity, which collectively determine functional outcomes and quality of life (1). Current thromboprophylaxis guidelines recommend risk-stratified approaches for ambulatory cancer patients receiving systemic therapy, with pharmacologic prophylaxis considered for those with Khorana scores ≥2 (32-34). However, these guidelines derive predominantly from chemotherapy-based regimens and do not specifically address ICI plus VEGF pathway inhibitor combinations. The observed VTE rates align with and extend existing evidence. The 12.4% 1-year VTE rate with ICI monotherapy in our sarcoma cohort is consistent with large cohort studies reporting 7.4–13% incidence at 6–12 months across multiple cancer types (12,13,35,36). Our findings extend this evidence base specifically to sarcoma, a population previously underrepresented in ICI-thrombosis literature. The numerically higher rate with combination therapy, while not statistically significant, parallels observations from other malignancies where combination ICI regimens and ICI-VEGF inhibitor combinations demonstrate incrementally increased thrombotic risk (17,37,38). The biologic plausibility of increased VTE risk with combination therapy is well established. ICI therapy promotes a prothrombotic inflammatory state through multiple pathways: aberrant immune activation increases circulating interleukin-6 and interleukin-8, driving neutrophil extracellular trap formation; activated T cells upregulate tissue factor expression on tumor and endothelial cells; and checkpoint blockade may disrupt immune homeostatic mechanisms that normally regulate coagulation (15,16,39). VEGF pathway inhibition compounds these risks by impairing endothelial integrity and nitric oxide signaling, reducing prostacyclin production, exposing subendothelial procoagulant phospholipids, and increasing blood viscosity through erythropoietin overproduction (19-21,23). When combined, these agents may exert additive or synergistic prothrombotic effects, particularly during the overlapping period of maximum vascular disruption. For sarcoma specifically, the clinical implications of VTE extend beyond medical management to surgical outcomes and functional recovery. Thrombotic events in the perioperative period delay definitive resection, potentially allowing tumor progression that precludes limb-salvage approaches or renders initially resectable disease unresectable (1,2). When therapeutic anticoagulation is required for VTE treatment, surgical bleeding risk increases substantially, potentially necessitating inferior vena cava filter placement with its attendant complications (4). Postoperatively, VTE impairs mobilization and rehabilitation, a critical determinant of functional outcomes in patients undergoing limb-sparing procedures (1,4). The high absolute VTE burden observed in both cohorts, therefore, represents a substantive threat to the primary treatment objectives of sarcoma care, independent of the incremental risk from combination therapy. These findings support clinical vigilance and risk assessment in sarcoma patients receiving ICI-based therapy. Current guidelines recommend risk-stratified thromboprophylaxis for ambulatory cancer patients based on the Khorana score, with pharmacologic prophylaxis considered for scores ≥2 (32-34). However, the Khorana score demonstrates limited discriminatory ability in ICI-treated populations and does not capture sarcoma-specific risk factors such as tumor location (particularly pelvic/thigh lesions), large tumor size (>8 cm), or perioperative status (1,2,40). Our observation of high VTE incidence in both treatment groups reinforces the need for sarcoma-specific risk stratification incorporating tumor characteristics and surgical planning. We did not detect evidence of increased musculoskeletal toxicity with combination therapy (HR 0.93, 95% CI: 0.61–1.41). Musculoskeletal immune-related adverse events, including myositis and inflammatory arthritis, occur in approximately 2–5% of ICI-treated patients and can substantially impact rehabilitation capacity (1). This finding suggests that concerns regarding compounding musculoskeletal toxicity should not preclude combination therapy when oncologically indicated. However, this observation does not diminish the importance of screening for the potentially life-threatening overlap syndrome of myositis, myocarditis, and myasthenia gravis, which occurs predominantly with combination ICI regimens and carries substantial mortality. Importantly, the direction of potential exposure misclassification in this study favors the null hypothesis. Because the monotherapy cohort was defined by the absence of a VEGF pathway inhibitor prescription within the initial 30-day window, patients who began a VEGF pathway inhibitor after this period remained classified as monotherapy recipients. Any such contamination of the monotherapy cohort with patients who actually received combination therapy during follow-up would attenuate the observed between-group difference, biasing the HR toward 1.0. Consequently, the point estimate of HR 1.23 may underestimate the true thrombotic risk associated with concurrent ICI and VEGF pathway inhibitor therapy. That a numerically elevated risk was observed despite this conservative classification bias lends additional plausibility to the hypothesis that combination therapy confers incremental VTE risk in this population. Limitations This study has important limitations. The retrospective design and reliance on administrative diagnosis codes may underascertain asymptomatic VTE and potentially misclassify events. Critically, TriNetX does not capture oncology-specific confounders, including disease stage, metastatic burden, ECOG performance status, sarcoma histologic subtype, line of therapy, or indication for VEGF pathway inhibitor use, any of which could substantially confound the treatment-VTE relationship. Additional unmeasured confounders not available in TriNetX include central venous catheter use, recent surgery or hospitalization, prior chemotherapy, and use of prophylactic anticoagulation, all of which could meaningfully affect observed VTE rates. In particular, patients receiving combination therapy may have more advanced disease, creating confounding by indication that propensity score matching on available covariates cannot fully address. Residual confounding, therefore, cannot be excluded. Furthermore, the study population encompasses a broad range of bone and soft tissue sarcoma histologies captured under ICD-10 codes C40, C41, C47, and C49. These subtypes differ substantially in biology, vascular involvement, surgical approach, and baseline thrombotic risk; subgroup analyses by sarcoma category were not feasible given sample size constraints. This heterogeneity represents a major limitation, as VTE risk determinants may vary meaningfully across histologic subtypes. Additionally, medication exposure was inferred from prescription records, and actual adherence or timing of drug administration relative to VTE events cannot be confirmed, introducing potential exposure misclassification. Specifically, the ±30-day co-prescription window used to define concurrent therapy may not capture the full duration of combination treatment, and patients in the monotherapy cohort who initiated a VEGF pathway inhibitor after the 30-day window were not reclassified. This misclassification is expected to be non-differential with respect to VTE outcome ascertainment and would bias estimates toward the null, potentially underestimating any true difference between cohorts. Information on concurrent supportive care measures, such as prophylactic anticoagulation, was also unavailable, which could influence observed VTE incidence. The competing risk of death was not formally modeled; in patients with advanced sarcoma, death may preclude VTE ascertainment and standard Kaplan-Meier analysis may overestimate VTE cumulative incidence in this setting. The study population represents patients captured within U.S.-based electronic health records and may not generalize to other healthcare settings. Finally, the relatively modest number of VTE events limits the statistical power to detect smaller but clinically meaningful differences. Given the observational design, residual confounding, and wide CIs, these results should be interpreted as hypothesis-generating rather than definitive. Nevertheless, because the principal sources of misclassification in this study bias toward the null, the observed point estimates likely represent a conservative bound on the true association between combination therapy and VTE risk, supporting the need for prospective evaluation with more granular exposure data. Conclusions In this real-world analysis of propensity-matched sarcoma patients, ICI-based therapy was associated with a substantial 1-year VTE burden regardless of the addition of a VEGF pathway inhibitor, with a numerically higher but statistically non-significant risk observed with combination therapy (HR 1.23, 95% CI: 0.91–1.66). The absence of a statistically significant difference should not be interpreted as evidence of equivalence, as the study was likely underpowered to detect clinically meaningful differences, and the predominant sources of exposure misclassification would bias estimates toward the null. No significant difference in musculoskeletal toxicity was identified between treatment groups, suggesting that compounding immune-related adverse events do not represent an additional barrier to combination therapy when indicated. Given the direct impact of thrombotic events on surgical candidacy, limb-salvage feasibility, and rehabilitation outcomes in sarcoma, the high absolute VTE rates observed in both cohorts underscore the need for systematic thrombotic risk assessment in this population. These findings are hypothesis-generating and highlight the need for prospective studies incorporating sarcoma-specific risk factors, histologic subtype, and disease stage to better characterize VTE risk and inform evidence-based thromboprophylaxis strategies for patients receiving ICI-based regimens. Supplementary The article’s supplementary files as Acknowledgments None. Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. This study was conducted in accordance with the Declaration of Helsinki and its subsequent amendments. Footnotes Reporting Checklist: The authors have completed the STROBE reporting checklist. Available at https://tcr.amegroups.com/article/view/10.21037/tcr-2026-0564/rc Funding: None. Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://tcr.amegroups.com/article/view/10.21037/tcr-2026-0564/coif). The authors have no conflicts of interest to declare. References Available at https://tcr.amegroups.com/article/view/10.21037/tcr-2026-0564/prf Supplementary Materials The article’s supplementary files as